Ability Biotherapeutics

Ability Biotherapeutics (also known as Ability Biologics) is a Montreal-based biotech founded in 2023 that engineers highly selective, immune-cell-modulating antibody therapeutics for cancer and autoimmune disease. Its AbiLeap discovery engine pairs continuously learning AI with one of the largest antibody-antigen interaction databases ever assembled to generate fully human, IgG-based multispecific antibodies that sense their environment and act only where intended - so-called logic-gated therapeutics. Backed by US$18M in seed capital led by Amplitude Ventures, the company is advancing a pipeline of immuno-oncology and autoimmune candidates toward preclinical readiness.